title: Pregabalin: as adjunctive treatment of partial seizures.
abstract: Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmitter release caused by binding to the alpha(2)-delta protein, resulting in allosteric modulation of P/Q-type voltage-gated calcium channels. In three well designed trials, oral pregabalin as adjunctive therapy in patients with refractory partial seizures was significantly (p < or = 0.0007) more effective than placebo in reducing seizure frequency when administered at dosages of 150-600 mg/day (as two or three divided doses). Adjunctive pregabalin produced an overall mean 41.3% improvement from baseline in 28-day seizure-free rate in four long-term (maximum exposure 1764 days), open-label studies in 1480 patients. CNS-related effects (e.g. dizziness and somnolence) were the most frequent dose-related treatment-emergent adverse events associated with adjunctive pregabalin therapy.
authors.affiliation: Adis International Limited, Auckland 1311, New Zealand.
authors.forename: Greg
authors.initials: G
authors.lastname: Warner
authors.forename: David P
authors.initials: DP
authors.lastname: Figgitt
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005062:European Union; D006801:Humans; D000069583:Pregabalin; D014481:United States; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D002121:Calcium Channel Blockers; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid
references.citation: Synapse. 2002 Sep 1;45(3):171-90
references.pmid: 12112396
references.citation: Drugs. 2004;64(24):2813-20; discussion 2821
references.pmid: 15563250
references.citation: CNS Drugs. 2006;20(8):685-93; discussion 694-5
references.pmid: 16863276
references.citation: J Clin Pharmacol. 2003 Mar;43(3):277-83
references.pmid: 12638396
references.citation: Clin Pharmacol Ther. 2003 Jun;73(6):491-505
references.pmid: 12811359
references.citation: Neurology. 2005 Feb 8;64(3):475-80
references.pmid: 15699378
references.citation: BMC Pharmacol. 2004 Aug 04;4:14
references.pmid: 15294026
references.citation: Expert Opin Investig Drugs. 2002 Oct;11(10):1387-406
references.pmid: 12387702
references.citation: Expert Opin Investig Drugs. 1999 Oct;8(10):1497-1510
references.pmid: 11139806
references.citation: Epilepsia. 2004;45 Suppl 6:13-8
references.pmid: 15315511
references.citation: J Pharmacol Exp Ther. 2000 Dec;295(3):1086-93
references.pmid: 11082444
references.citation: Epilepsia. 2004 Jan;45(1):20-7
references.pmid: 14692903
references.citation: Neurology. 2003 May 27;60(10):1631-7
references.pmid: 12771254
references.citation: Epilepsy Res. 2001 Jan;43(1):11-58
references.pmid: 11137386
references.citation: J Psychopharmacol. 2003 Jun;17(2):174-8
references.pmid: 12870563
references.citation: Neurosci Lett. 2000 Feb 18;280(2):107-10
references.pmid: 10686389
references.citation: Neurology. 2000;55(11 Suppl 3):S17-24
references.pmid: 11147564
references.citation: Epilepsia. 2001 Jun;42(6):790-2
references.pmid: 11422338
references.citation: Drugs. 2005;65(1):111-8; discussion 119-20
references.pmid: 15610058
references.citation: Neuropharmacology. 2002 Feb;42(2):229-36
references.pmid: 11804619